The New Rules of Biotech: A Founder's Guide to Building Great Companies

· D. Craig Consulting LLC
Ebook
415
Pages
Eligible

About this ebook

Between 2020 and 2023, biotech ran the full cycle: a historic boom, a brutal unwinding, and a reset that rewrote how companies get built and funded. The founders succeeding today aren't running the 2021 playbook. They can't.

The New Rules of Biotech is a candid, operator's-eye guide to starting and building a biotech company in the world that came after the reset. Drawing on three decades in drug development and the hard lessons of building a company from the lab bench up, David Craig walks founders through the full arc, from the question you should ask before you ever incorporate to the exit most companies will actually take.

There's no hype here and no theory for its own sake. Just the decisions that matter and the traps that end companies: the new cost of capital, what the FDA and the IRA expect now, platform versus asset, the modern seed round, non-dilutive capital as a strategy, term sheets that don't bite back, the clinical path from IND through proof-of-concept, manufacturing, business development, acquisition, and knowing when to stop.

For first-time founders, scientist-entrepreneurs, and anyone raising or building in biotech today, it's a field guide for doing the work with clear eyes, and for remembering, when it's hard, exactly why you started.

Between 2020 and 2023, biotech ran the full cycle: a historic boom, a brutal unwinding, and a reset that rewrote how companies get built and funded. The founders succeeding today aren't running the 2021 playbook. They can't. The New Rules of Biotech is a candid, operator's-eye guide to starting a...

Discover more

About the author

David Craig is the president and CEO of Sarcomatrix Therapeutics, a virtual, pre-IND biotech developing oral small-molecule and protein therapies for Duchenne muscular dystrophy and other neuromuscular diseases. A pharmacist by training with an MBA, he built and developed therapeutics at Amgen, Gilead, and Portola Pharmaceuticals before co-founding Sarcomatrix in 2022 to carry forward science he was convinced would otherwise sit on a shelf.

His interest in muscle disease is not abstract; it runs through his own family, and this book is dedicated to them. The New Rules of Biotech is the field guide he wishes he'd had when he started.

David Craig is the president and CEO of Sarcomatrix Therapeutics, a virtual, pre-IND biotech developing oral small-molecule and protein therapies for Duchenne muscular dystrophy and other neuromuscular diseases. A pharmacist by training with an MBA, he built and developed therapeutics at Amgen, G...

Rate this ebook

Tell us what you think.

Reading information

Smartphones and tablets
Install the Google Play Books app for Android and iPad/iPhone. It syncs automatically with your account and allows you to read online or offline wherever you are.
Laptops and computers
You can listen to audiobooks purchased on Google Play using your computer's web browser.
eReaders and other devices
To read on e-ink devices like Kobo eReaders, you'll need to download a file and transfer it to your device. Follow the detailed Help Center instructions to transfer the files to supported eReaders.